Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MB | P02144 | 2/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3278273 | 0.78 | MB (0.44) | MBPDE3BPDE3AMAPK1CYP11B1 | |
| SCHEMBL4044760 | 0.75 | PDE3B (0.48) | PDE3BPDE3A | |
| SCHEMBL14042006 | 0.74 | PDE3B (0.46) | PDE3BPDE3A | |
| SCHEMBL15074619 | 0.72 | MB (0.66) | MBPDE3BPDE3AMAPK1CYP11B1 | |
| SCHEMBL1270310 | 0.71 | MB (0.56) | MBPDE3BPDE3AMAPK1CYP11B1 | |
| SCHEMBL29547390 | 0.71 | MB (0.56) | MBPDE3BPDE3AMAPK1CYP11B1 | |
| SCHEMBL31310121 | 0.71 | PIK3CD (0.36) | MBMAPK1 | |
| SCHEMBL25462291 | 0.71 | HPGD (0.41) | MAPK1 | |
| SCHEMBL3278321 | 0.70 | MB (0.41) | MBMAPK1 | |
| SCHEMBL3277903 | 0.70 | MB (0.41) | MB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. | 2016-06-09 | — | — | US | disclosed |
| US-7022721-B1 | Method and composition for rejuvenating cells, tissues, organs, hair and nails | ULRICH PETER C | 2006-04-04 | — | — | US | disclosed |
| US-20050245512-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | ULRICH PETER C | 2005-11-03 | — | — | US | disclosed |
| US-6777557-B2 | Method and composition for rejuvenating cells, tissues organs, hair and nails | FARRINGTON PHARMACEUTICALS, LLC | 2004-08-17 | — | — | US | disclosed |
| US-20020188015-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | FARRINGTON PHARMACEUTICALS, LLC | 2002-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188015-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | TERT, TELO2, HKDC1 | MB 4025/4885PDE3B 3391/4885PDE3A 2960/4885 |
| US-20050245512-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | TERT, TELO2, HKDC1 | MB 4025/4885PDE3B 3391/4885PDE3A 2960/4885 |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | MB 4704/4885PDE3B 3972/4885PDE3A 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.